STOCK TITAN
  1. Home
  2. Sec-filings
  3. RADX
  4. [SCHEDULE 13G] Radiopharm Theranostics Limited American SEC Filing

[SCHEDULE 13G] Radiopharm Theranostics Limited American SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock RADX logo
Radiopharm Theranostics Ltd

NASDAQ:RADX

RADX Rankings

#7687 Ranked by Market Cap
N/A Ranked by Dividends

RADX Latest News

Jul 22, 2025
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
Jun 24, 2025
Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
Jun 11, 2025
Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
Jun 4, 2025
Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors
Jun 2, 2025
Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake

RADX Latest SEC Filings

Jul 21, 2025
[6-K] Radiopharm Theranostics Limited American Current Report (Foreign Issuer)
Jul 16, 2025
[SCHEDULE 13G/A] Radiopharm Theranostics Limited American SEC Filing
Jul 16, 2025
[6-K] Radiopharm Theranostics Limited American Current Report (Foreign Issuer)
Jun 23, 2025
[6-K] Radiopharm Theranostics Limited American Current Report (Foreign Issuer)

RADX Stock Data

32.71M
7.88M
6.77%
0.53%
Biotechnology
Healthcare
Link
Australia
Carlton